Geron Corp (GERN)

[healthywelth]

Geron's Imetelstat Reaffirmed as a Priority for Johnson & Johnson
Wednesday, 18 July 2018 15:04 (EST)The chart below summarizes Janssen's pipeline of new molecular entities (NMEs). We note that Janssen continues to list Geron's imetelstat as the first oncology asset in its pipeline. Reinforcing this priority, Mr. Gorsky cited two areas of oncology—prostate cancer (for which Janssen earned an FDA approval earlier this year) and hematology (which is obviously Geron's area of focus)—as Janssen's principal catalysts for growth for the remainder of this year. We believe that the mentions of imetelstat at the top of the priority list in the pipeline and at the top of Mr. Gorsky's comments on Janssen are not merely coincidental; rather, we take this as a solid indicator of Janssen's commitment to imetelstat as a potential billion dollar therapeutic

https://www.equities.com/news/geron-s-imetelstat-reaffirmed-as-a-priority-for-johnson-johnson